Literature DB >> 32015991

Sequential treatment of metastatic renal cancer in a complex evolving landscape.

Javier C Angulo1, Charles H Lawrie2, José I López3.   

Abstract

Entities:  

Year:  2019        PMID： 32015991      PMCID： PMC6976503          DOI： 10.21037/atm.2019.12.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

Authors:  Laurence Albiges; Tom Powles; Michael Staehler; Karim Bensalah; Rachel H Giles; Milan Hora; Markus A Kuczyk; Thomas B Lam; Börje Ljungberg; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Axel Bex
Journal:  Eur Urol       Date:  2019-08       Impact factor: 20.096

2.  Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.

Authors:  José I López; Rafael Pulido; Jesús M Cortés; Javier C Angulo; Charles H Lawrie
Journal:  Pathol Res Pract       Date:  2018-06-12       Impact factor: 3.250

3.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Authors:  Guillermo de Velasco; Axel Bex; Laurence Albiges; Thomas Powles; Brian I Rini; Robert J Motzer; Daniel Y C Heng; Bernard Escudier
Journal:  Eur Urol Oncol       Date:  2019-08-01

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  A divide-and-conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in routine pathology: A modeling approach in clear cell renal cell carcinoma.

Authors:  José I Lopez; Jesús M Cortes
Journal:  F1000Res       Date:  2016-03-22

8.  Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.

Authors:  Sabrina Rossetti; Carmine D'Aniello; Gelsomina Iovane; Sarah Scagliarini; Maria M Laterza; Fernando De Vita; Clementina Savastano; Giacomo Cartenì; Maria A Porricelli; Massimiliano Berretta; Salvatore Pisconti; Gaetano Facchini; Carla Cavaliere
Journal:  Front Pharmacol       Date:  2017-07-20       Impact factor: 5.810

9.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.

Authors:  Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Tim Chambers; Jose I Lopez; David Nicol; Tim O'Brien; James Larkin; Stuart Horswell; Mark Stares; Lewis Au; Mariam Jamal-Hanjani; Ben Challacombe; Ashish Chandra; Steve Hazell; Claudia Eichler-Jonsson; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Faiz Jabbar; Lavinia Spain; Sharanpreet Lall; Rosa Guarch; Mary Falzon; Ian Proctor; Lisa Pickering; Martin Gore; Thomas B K Watkins; Sophia Ward; Aengus Stewart; Renzo DiNatale; Maria F Becerra; Ed Reznik; James J Hsieh; Todd A Richmond; George F Mayhew; Samantha M Hill; Catherine D McNally; Carol Jones; Heidi Rosenbaum; Stacey Stanislaw; Daniel L Burgess; Nelson R Alexander; Charles Swanton
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

10.  Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.

Authors:  Yoshifumi Kadono; Hiroyuki Konaka; Kouji Izumi; Satoshi Anai; Kiyohide Fujimoto; Kei Ishibashi; Noriyasu Kawai; Taku Kato; Akinori Iba; Naoya Masumori; Kenichi Yoshimura; Atsushiu Mizokami
Journal:  Contemp Clin Trials Commun       Date:  2019-06-26
View more
  4 in total

1.  Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.

Authors:  Marta Vilaça; Fátima Braga; Alexandra Mesquita
Journal:  Cureus       Date:  2022-03-29

2.  Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices.

Authors:  Nicholas J Salgia; Errol J Philip; Mohammadbagher Ziari; Kelly Yap; Sumanta Kumar Pal
Journal:  J Clin Med       Date:  2020-05-17       Impact factor: 4.241

3.  Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.

Authors:  Gorka Larrinaga; Jon Danel Solano-Iturri; Peio Errarte; Miguel Unda; Ana Loizaga-Iriarte; Amparo Pérez-Fernández; Enrique Echevarría; Aintzane Asumendi; Claudia Manini; Javier C Angulo; José I López
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 4.  Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.

Authors:  Alessandro Comandone; Federica Vana; Tiziana Comandone; Marcello Tucci
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.